microRNA-135b has a neuroprotective role via targeting of β-site APP-cleaving enzyme 1

Experimental and Therapeutic Medicine

Volumn 12, Issue 2, 2016, Pages 809-814

  Zhang, Yi ^a   Xing, Hongxia ^a   Guo, Shuangxi ^a   Zheng, Zhiyong ^a   Wang, Haoliang ^a   Xu, Dawei ^a  

^a The First Affiliated Hospital of Xinxiang Medical University   (China)

Author keywords

Alzheimer s disease; microRNA; Neuroprotective; site APP cleaving enzyme 1

Indexed keywords

BETA SECRETASE 1; MICRORNA; MICRORNA 135B; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HIPPOCAMPAL NEURONAL CULTURE; HUMAN; LEARNING; LUCIFERASE ASSAY; MALE; MEMORY; MOUSE; MTT ASSAY; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; WESTERN BLOTTING; Y-MAZE TEST;

EID: 84974707596     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2016.3366     Document Type: Article

References (30)

1. Zlomuzica A, Dere D, Binder S, De Souza Silva MA, Huston JP and Dere E: Neuronal histamine and cognitive symptoms in Alzheimer’s disease. Neuropharmacology: May 27, 2015 (Epub ahead of print).
2. Dezsi L, Tuka B, Martos D and Vecsei L: Alzheimer’s disease, astrocytes and kynurenines. Curr Alzheimer Res 12: 462-480, 2015.
3. Alzheimer’s Association: 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 11: 332-384, 2015
4. Lei X, Lei L, Zhang Z, Zhang Z and Cheng Y: Downregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer’s disease. Int J Clin Exp Pathol 8: 1565-1574, 2015.
5. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
6. Yang G, Song Y, Zhou X, Deng Y, Liu T, Weng G, Yu D and Pan S: DNA methyltransferase 3, a target of microRNA-29c, contributes to neuronal proliferation by regulating the expression of brain-derived neurotrophic factor. Mol Med Rep 12: 1435-1442, 2015.
7. Stary CM, Xu L, Sun X, Ouyang YB, White RE, Leong J, Li J, Xiong X and Giffard RG: MicroRNA-200c contributes to injury from transient focal cerebral ischemia by targeting Reelin. Stroke 46: 551-556, 2015.
8. Denk J, Boelmans K, Siegismund C, Lassner D, Arlt S and Jahn H: MicroRNA Profiling of CSF reveals potential biomarkers to detect Alzheimer’s disease. PLoS One 10: e0126423, 2015.
9. Yang G, Song Y, Zhou X, Deng Y, Liu T, Weng G, Yu D and Pan S: MicroRNA-29c targets β -site amyloid precursor protein-cleaving enzyme 1 and has a neuroprotective role in vitro and in vivo. Mol Med Rep, 2015.
10. Zhu Y, Li C, Sun A, Wang Y and Zhou S: Quantification of microRNA-210 in the cerebrospinal fluid and serum: Implications for Alzheimer’s disease. Exp Ther Med 9: 1013-1017, 2015.
11. Liu CG, Wang JL, Li L, Xue LX, Zhang YQ and Wang PC: MicroRNA-135a and -200b, potential Biomarkers for Alzheimer’s disease, regulate β secretase and amyloid precursor protein. Brain Res 1583: 55-64, 2014.
12. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
13. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Washington (DC). 8th edition. National Academies Press, US, 2011.
14. Hansen HH, Fabricius K, Barkholt P, Niehoff ML, Morley JE, Jelsing J, Pyke C, Knudsen LB, Farr SA and Vrang N: The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer’s disease. J Alzheimers Dis 46: 877-888, 2015.
15. Takagane K, Nojima J, Mitsuhashi H, Suo S, Yanagihara D, Takaiwa F, Urano Y, Noguchi N and Ishiura S: Aβ induces oxidative stress in senescence-accelerated (SAMP8) mice. Biosci Biotechnol Biochem 79: 912-918, 2015.
16. Decourt B, Walker A, Gonzales A,Malek-Ahmadi M, Liesback C, Davis KJ, Belden CM, Jacobson SA and Sabbagh MN: Can platelet BACE1 levels be used as a biomarker for Alzheimer’s disease? Proof-of-concept study. Platelets 24: 235-238, 2013.
17. Shaw LM, Vanderstichele H, Knapik-Czajka M,Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P et al: Alzheimer’s Disease Neuroimaging Initiative: Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65: 403-413, 2009.
18. Bibl M, Esselmann H, Lewczuk P, Trenkwalder CF, Otto M, Kornhuber J, Wiltfang J and Mollenhauer B: Combined analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Int J Alzheimers Dis 2010: Article ID 761571, 2010.
19. Hébert SS, Horré K, Nicolaï L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A and De Strooper B: Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 105: 6415-6420, 2008.
20. Müller M, Kuiperij HB, Claassen JA, Küsters B and Verbeek MM: MicroRNAs in Alzheimer’s disease: Differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging 35: 152-158, 2014.
21. Moon M, Cha MY and Mook-Jung I: Impaired hippocampal neurogenesis and its enhancement with ghrelin in 5XFAD mice. J Alzheimers Dis 41: 233-241, 2014.
22. Cui Y, Xiao Z, Han J,Sun J, Ding W, Zhao Y, Chen B, Li X and Dai J: MiR-125b orchestrates cell proliferation, differentiation and migration in neural stem/progenitor cells by targeting Nestin. BMC Neurosci 13: 116, 2012.
23. Mollinari C, Racaniello M, Berry A, Pieri M, de Stefano MC, Cardinale A, Zona C, Cirulli F, Garaci E and Merlo D: miR-34a regulates cell proliferation, morphology and function of newborn neurons resulting in improved behavioural outcomes. Cell Death Dis 6: e1622, 2015.
24. Buckley RF, Ellis KA, Ames D, Rowe CC, Lautenschlager NT, Maruff P, Villemagne VL, Macaulay SL, Szoeke C, Martins RN et al: Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer’s disease. Neuropsychology 29: 571-581, 2015.
25. Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC and Lichtenthaler SF: Function, therapeutic potential and cell biology of BACE proteases: Current status and future prospects. J Neurochem 130: 4-28, 2014.
26. Yan R and Vassar R: Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol 13: 319-329, 2014.
27. Long JM, Ray B and Lahiri DK: MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J Biol Chem 289: 5184-5198, 2014.
28. Zhu HC, Wang LM, Wang M, Song B, Tan S, Teng JF and Duan DX: MicroRNA-195 downregulates Alzheimer’s disease amyloid-beta production by targeting BACE1. Brain Res Bull 88: 596-601, 2012.
29. Roshan R, Ghosh T, Gadgil M and Pillai B: Regulation of BACE1 by miR-29a/b in a cellular model of Spinocerebellar Ataxia 17. RNA Biol 9: 891-899, 2012.
30. Fang M, Wang J, Zhang X, Geng Y, Hu Z, Rudd JA, Ling S, Chen W and Han S: The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer’s disease. Toxicol Lett 209: 94-105, 2012.